Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Fie J Vojdeman; Sarah E M Herman; Nikolai Kirkby; Adrian Wiestner; Mars B van T' Veer; Geir E Tjønnfjord; Maija A Itälä-Remes; Eva Kimby; Mohammed Z Farooqui; Aaron Polliack; Ka Lung Wu; Jeanette K Doorduijn; Wendimagegn G Alemayehu; Shulamiet Wittebol; Tomas Kozak; Jan Walewski; Martine C J Abrahamse-Testroote; Marinus H J van Oers; Christian H Geisler; Carsten U Niemann

doi:10.1080/10428194.2017.1285027

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Fie J Vojdeman, Sarah E M Herman, Nikolai Kirkby, Adrian Wiestner, Mars B van T' Veer, Geir E Tjønnfjord, Maija A Itälä-Remes, Eva Kimby, Mohammed Z Farooqui, Aaron Polliack, Ka Lung Wu, Jeanette K Doorduijn, Wendimagegn G Alemayehu, Shulamiet Wittebol, Tomas Kozak, Jan Walewski, Martine C J Abrahamse-Testroote, Marinus H J van Oers, Christian H Geisler, Carsten U Niemann

Department of Clinical Medicine

6 Citations (Scopus)

Abstract

CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.

Original language	English
Journal	Leukemia and Lymphoma
Volume	58
Issue number	10
Pages (from-to)	2356-2362
ISSN	1042-8194
DOIs	https://doi.org/10.1080/10428194.2017.1285027
Publication status	Published - 3 Oct 2017

Access to Document

10.1080/10428194.2017.1285027

Cite this

Vojdeman, F. J., Herman, S. E. M., Kirkby, N., Wiestner, A., van T' Veer, M. B., Tjønnfjord, G. E., Itälä-Remes, M. A., Kimby, E., Farooqui, M. Z., Polliack, A., Wu, K. L., Doorduijn, J. K., Alemayehu, W. G., Wittebol, S., Kozak, T., Walewski, J., Abrahamse-Testroote, M. C. J., van Oers, M. H. J., Geisler, C. H., & Niemann, C. U. (2017). Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia. Leukemia and Lymphoma, 58(10), 2356-2362. https://doi.org/10.1080/10428194.2017.1285027

Vojdeman, FJ, Herman, SEM, Kirkby, N, Wiestner, A, van T' Veer, MB, Tjønnfjord, GE, Itälä-Remes, MA, Kimby, E, Farooqui, MZ, Polliack, A, Wu, KL, Doorduijn, JK, Alemayehu, WG, Wittebol, S, Kozak, T, Walewski, J, Abrahamse-Testroote, MCJ, van Oers, MHJ, Geisler, CH & Niemann, CU 2017, 'Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia', Leukemia and Lymphoma, vol. 58, no. 10, pp. 2356-2362. https://doi.org/10.1080/10428194.2017.1285027

@article{b2f0db7898e24c6e8987ea7b23aa1848,

title = "Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia",

abstract = "CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.",

author = "Vojdeman, {Fie J} and Herman, {Sarah E M} and Nikolai Kirkby and Adrian Wiestner and {van T' Veer}, {Mars B} and Tj{\o}nnfjord, {Geir E} and It{\"a}l{\"a}-Remes, {Maija A} and Eva Kimby and Farooqui, {Mohammed Z} and Aaron Polliack and Wu, {Ka Lung} and Doorduijn, {Jeanette K} and Alemayehu, {Wendimagegn G} and Shulamiet Wittebol and Tomas Kozak and Jan Walewski and Abrahamse-Testroote, {Martine C J} and {van Oers}, {Marinus H J} and Geisler, {Christian H} and Niemann, {Carsten U}",

year = "2017",

month = oct,

day = "3",

doi = "10.1080/10428194.2017.1285027",

language = "English",

volume = "58",

pages = "2356--2362",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis",

number = "10",

}

TY - JOUR

T1 - Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

AU - Vojdeman, Fie J

AU - Herman, Sarah E M

AU - Kirkby, Nikolai

AU - Wiestner, Adrian

AU - van T' Veer, Mars B

AU - Tjønnfjord, Geir E

AU - Itälä-Remes, Maija A

AU - Kimby, Eva

AU - Farooqui, Mohammed Z

AU - Polliack, Aaron

AU - Wu, Ka Lung

AU - Doorduijn, Jeanette K

AU - Alemayehu, Wendimagegn G

AU - Wittebol, Shulamiet

AU - Kozak, Tomas

AU - Walewski, Jan

AU - Abrahamse-Testroote, Martine C J

AU - van Oers, Marinus H J

AU - Geisler, Christian H

AU - Niemann, Carsten U

PY - 2017/10/3

Y1 - 2017/10/3

N2 - CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.

AB - CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.

U2 - 10.1080/10428194.2017.1285027

DO - 10.1080/10428194.2017.1285027

M3 - Journal article

C2 - 28278728

SN - 1042-8194

VL - 58

SP - 2356

EP - 2362

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 10

ER -

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Abstract

Access to Document

Fingerprint

Cite this